ライフサイエンスコーパス: coronary heart disease

1 ardial infarction, ischemic stroke, or fatal coronary heart disease).

2 lipoprotein(a) pathway is a causal factor in coronary heart disease.

3 circulating lipoprotein(a) concentration, to coronary heart disease.

4 bsequent events among those with established coronary heart disease.

5 sequence variants previously associated with coronary heart disease.

6 ciated with total cardiovascular disease and coronary heart disease.

7 over the determinants and natural history of coronary heart disease.

8 cardiometabolic traits, type 2 diabetes, and coronary heart disease.

9 I-C fusion partner-like 2) with hard and all coronary heart disease.

10 cus to be associated with increased risk for coronary heart disease.

11 luding death from cardiovascular disease and coronary heart disease.

12 d with increased risk of type 2 diabetes and coronary heart disease.

13 ascular disease and 15% to 23% lower risk of coronary heart disease.

14 sulfonylurea therapy may reduce the risk of coronary heart disease.

15 of evidence-based treatments for established coronary heart disease.

16 (LDL) strongly correlates with incidence of coronary heart disease.

17 novel genetic loci that are associated with coronary heart disease.

18 onal association of plasma urate and risk of coronary heart disease.

19 ss multiple ethnicities, as well as clinical coronary heart disease.

20 l atherosclerosis and the risk of subsequent coronary heart disease.

21 ed with elevated risk of developing clinical coronary heart disease.

22 e to permanent metal stents for treatment of coronary heart disease.

23 on in a large cohort of patients with proven coronary heart disease.

24 rdiovascular cause of death had a history of coronary heart disease.

25 ratios were consistently high for death from coronary heart disease.

26 nsity lipoprotein levels, as well as risk of coronary heart disease.

27 have been implicated in atherosclerosis and coronary heart disease.

28 val, 48-97; P<0.001) of the decline in total coronary heart disease.

29 over 6 years in 9014 patients with previous coronary heart disease.

30 atin-using patients with established, stable coronary heart disease.

31 atin-using patients with established, stable coronary heart disease.

32 iovascular disease, and those with prevalent coronary heart disease.

33 JAK2 were each individually associated with coronary heart disease.

34 ation, or both were causally associated with coronary heart disease.

35 le lipid profiles, have reduced incidence of coronary heart disease.

36 s involving 10 195 patients with established coronary heart disease.

37 are independent and causal risk factors for coronary heart disease.

38 3, and had a previous history of MI, IS, or coronary heart disease.

39 walked at a pace >3 mph had a lower risk of coronary heart disease (0.50; confidence interval, 0.38-

40 (relative risk [RR] 0.80, 95% CI 0.77-0.83), coronary heart disease (0.83, 0.78-0.88), stroke (0.73,

41 5% confidence interval (CI): 1.04, 1.22) for coronary heart disease, 1.20 (95% CI: 1.01, 1.42) for he

42 ce interval [CI], 3.9 to 6.1) for death from coronary heart disease, 2.6 (95% CI, 1.7 to 4.1) for dea

43 e, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); a

44 r cardiovascular disease events was 41%, for coronary heart disease 25%, for stroke 26%, for heart fa

45 SD, 10.2] years; 246 women [50.1%]; 170 with coronary heart disease [34.6%]; entry mean LDL-C level,

46 including 506100 from heart disease (371266 coronary heart disease, 35019 hypertensive heart disease

47 l; 3) diabetes mellitus; 4) hypertension; 5) coronary heart disease; 6) hyperlipidemia; 7) alcohol ab

48 ions between PCSK9 LOF variants and incident coronary heart disease (851 events in blacks and 2662 ev

49 -110.0 (95% CI, -128.9 to -91.1); death from coronary heart disease, -91.9 (95% CI, -108.9 to -75.0);

50 ciated with total cardiovascular disease and coronary heart disease after adjustment for cardiovascul

51 ariants at the CXCR4 locus with the risk for coronary heart disease, along with CXCR4 transcript expr

52 hazard ratios for cardiovascular disease and coronary heart disease among participants who consumed 1

53 adjusted mean DLR of 0.41 (SD, 0.12) for all coronary heart disease and 0.54 (SD, 0.12) for CVD, foll

54 ign and genetic data on 60 801 patients with coronary heart disease and 123 504 controls from the CAR

55 In 60 801 patients with coronary heart disease and 123 504 controls, OR for myoc

56 comprising 106 353 patients with established coronary heart disease and 19 332 deaths in 22 studies o

57 ld cohort differences in rates of death from coronary heart disease and 3-fold differences in rates o

58 hat together enrolled 4726 participants with coronary heart disease and 3529 controls.

59 um score was the most important predictor of coronary heart disease and all atherosclerotic cardiovas

60 thy lifestyle were compared for all and hard coronary heart disease and all CVD events over the 10-ye

61 Coronary heart disease and all-cause deaths were ascerta

62 recognized as an independent risk factor for coronary heart disease and cardiovascular mortality.

63 ASCV mortality, defined as death because of coronary heart disease and cerebrovascular or other athe

64 erebral hemorrhage, subarachnoid hemorrhage, coronary heart disease and death due to the vascular dis

65 ding autoimmune diseases, schizophrenia, and coronary heart disease and evidence suggesting previousl

66 ox proportional-hazards models with incident coronary heart disease and heart failure as time-depende

67 ities) who were aged 69 to 82 years, free of coronary heart disease and heart failure, and underwent

68 on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is

69 Chinese patients with coronary heart disease and impaired glucose tolerance we

70 INTERPRETATION: In Chinese patients with coronary heart disease and impaired glucose tolerance, a

71 events in Chinese patients with established coronary heart disease and impaired glucose tolerance, a

72 The effect of pravastatin versus placebo on coronary heart disease and major adverse cardiovascular

73 en reported to be negatively associated with coronary heart disease and may predict disease prevalenc

74 LDL-C lowering, despite a high prevalence of coronary heart disease and risk factors.

75 and 67% (HR: 0.33; 95% CI: 0.19 to 0.57) for coronary heart disease and stroke combined (p for trend

76 978, a sharp decline in mortality rates from coronary heart disease and stroke has become unmistakabl

77 century, then the decline in mortality from coronary heart disease and stroke has been the success s

78 cluded that a significant recent downtick in coronary heart disease and stroke mortality rates had de

79 f PCSK9 LOF variants with LDL-C and incident coronary heart disease and stroke through a meta-analysi

80 The early phase of this decline in coronary heart disease and stroke was unexpected and con

81 Outcomes included cumulative CVD (coronary heart disease and stroke) deaths prevented or p

82 enders an increase in central (aortic) BP in coronary heart disease and, as a consequence, fails to d

83 of cardiovascular disease (i.e., stroke and coronary heart disease) and type 2 diabetes.

84 reported was 32 [13%] of 247 individuals for coronary heart disease), and respiratory conditions (eg,

85 ad suffered from CVD, 4.9% had suffered from coronary heart disease, and 2.6% had experienced a strok

86 benefit of strenuous PA for total mortality, coronary heart disease, and breast cancer reported in ot

87 lthier lifestyles and fewer risk factors for coronary heart disease, and particularly those with favo

88 justing for Framingham risk score variables, coronary heart disease, and renal function.

89 for BMI at baseline and for type 2 diabetes, coronary heart disease, and stroke at baseline and follo

90 iation of ideal CVH with mortality, incident coronary heart disease, and stroke events in elderly ind

91 ic types of nuts and cardiovascular disease, coronary heart disease, and stroke risk.

92 ity (ie, at least two from: type 2 diabetes, coronary heart disease, and stroke) in adults who are ov

93 veloping at least two from: type 2 diabetes, coronary heart disease, and stroke).

94 dent myocardial infarction or death owing to coronary heart disease, and stroke, defined as the first

95 ve hypertension, chronic kidney disease, HF, coronary heart disease, and stroke.

96 Prevalence of hypertension, coronary heart disease, and type 2 diabetes were determi

97 recommendations for patients with prevalent coronary heart disease, and we offer recommendations, wh

98 L, no microalbuminuria, no family history of coronary heart disease (any/premature), absence of metab

99 Although the magnitude of benefit for coronary heart disease appeared to be moderate, in part

100 ther contemporary trends in the incidence of coronary heart disease are associated with changes in mo

101 osis because current diagnostic criteria for coronary heart disease are not met.

102 of LNK single-nucleotide polymorphisms with coronary heart disease are poorly understood.

103 the incidence and morbidity of hypertension, coronary heart disease, arrhythmia, heart failure, and s

104 with low-density lipoprotein cholesterol and coronary heart disease at APOB were cis-methylation quan

105 Antidiastole of coronary heart disease, atrial septal defect, and atrial

106 SMT (CR+SMT), with assessments of stress and coronary heart disease biomarkers obtained before and af

107 significant, and comparable, improvements in coronary heart disease biomarkers.

108 frequently been studied as risk factors for coronary heart disease but not for HF.

109 entration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycae

110 causal role for urate in the development of coronary heart disease, but these estimates might be inf

111 elected patient populations with established coronary heart disease, but whether OMT modifies the tre

112 lar disease, pravastatin reduced the risk of coronary heart disease by 27% (P=0.002) and major advers

113 /=190 mg/dL, pravastatin reduced the risk of coronary heart disease by 27% (P=0.033) and major advers

114 ardiovascular disease cases, including 8,390 coronary heart disease cases and 5,910 stroke cases.

115 rs), 1203 incident CVD events, including 916 coronary heart disease cases, were reported.

116 althy obese individuals had a higher risk of coronary heart disease, cerebrovascular disease, and hea

117 nary artery calcium (CAC) is associated with coronary heart disease (CHD) and cardiovascular disease

118 The association of coronary heart disease (CHD) and human immunodeficiency

119 cancer were the primary trial outcomes, and coronary heart disease (CHD) and overall CVD were additi

120 Incident ASCVD events including coronary heart disease (CHD) and stroke.

121 s study was to identify the risk factors for coronary heart disease (CHD) and to quantify the effects

122 or physical activity in patients with stable coronary heart disease (CHD) are based on modest evidenc

123 Common diseases such as coronary heart disease (CHD) are complex in etiology.

124 in 14 prospective studies supplemented with coronary heart disease (CHD) data from CARDIoGRAMplusC4D

125 D, including nonfatal myocardial infarction, coronary heart disease (CHD) death, and stroke.

126 ine (2000-2002), in predicting time to first coronary heart disease (CHD) event (median follow-up, 10

127 rmine the long-term risks of acute and fatal coronary heart disease (CHD) events after sepsis hospita

128 These patients may be at increased risk for coronary heart disease (CHD) events and mortality.

129 Prospective studies linking shift work to coronary heart disease (CHD) have been inconsistent and

130 ical guideline on the value of screening for coronary heart disease (CHD) in asymptomatic persons.

131 iation between flavonoid intake and incident coronary heart disease (CHD) in geographically and racia

132 ve protein (hs-CRP) has been associated with coronary heart disease (CHD) in numerous but not all obs

133 , has been associated with increased risk of coronary heart disease (CHD) in observational studies, b

134 tion of cardiovascular risk in patients with coronary heart disease (CHD) is needed to inform treatme

135 Blacks have higher coronary heart disease (CHD) mortality compared with whi

136 count appears to predict total mortality and coronary heart disease (CHD) mortality, but it is unclea

137 Plant-based diets are recommended for coronary heart disease (CHD) prevention.

138 se association between physical activity and coronary heart disease (CHD) risk has primarily been sho

139 a-linolenic acid (ALA, 18:3; n-3) may reduce coronary heart disease (CHD) risk, but the results of pr

140 2 diabetes is considered to be equivalent to coronary heart disease (CHD) risk, there is considerable

141 of asymptomatic individuals with respect to coronary heart disease (CHD) risk.

142 Whether disclosing genetic risk for coronary heart disease (CHD) to individuals influences i

143 low-up, 329 men died from CVD, 148 died from coronary heart disease (CHD), and 72 men died from strok

144 orted to be associated with risk of incident coronary heart disease (CHD), and blood urea nitrogen (B

145 telomere length (TL) to be a risk factor for coronary heart disease (CHD), and recently the associati

146 differences of incident heart failure (HF), coronary heart disease (CHD), and stroke in participants

147 ommended in guidelines for the management of coronary heart disease (CHD), concerns have been raised

148 tion between primary low HDL cholesterol and coronary heart disease (CHD), CVD, and all-cause death a

149 ascular disease (CVD) mortality and incident coronary heart disease (CHD), CVD, and cancer over a mea

150 ever, whether it is associated with incident coronary heart disease (CHD), especially in women, and w

151 learance pathway that are protective against coronary heart disease (CHD), independently of LDL chole

152 relevant in type 2 diabetes mellitus (T2DM), coronary heart disease (CHD), ischemic stroke, and heart

153 .6 mm Hg) with all-cause mortality, incident coronary heart disease (CHD), stroke, and ESRD was exami

154 ivity cardiac troponin-T [hs-cTnT]) and with coronary heart disease (CHD), stroke, or death over 21 y

155 enetic etiology of type 2 diabetes (T2D) and coronary heart disease (CHD), we conducted a genome-wide

156 een exposure to multiple metals and incident coronary heart disease (CHD).

157 HDL defined by apoC-III are associated with coronary heart disease (CHD).

158 has been associated with type 2 diabetes and coronary heart disease (CHD).

159 ctivity is associated with decreased risk of coronary heart disease (CHD).

160 n plasma are associated with a lower risk of coronary heart disease (CHD).

161 d profile that may increase women's risk for coronary heart disease (CHD).

162 consumption to blood lipid levels and hence coronary heart disease (CHD).

163 , 58.5 years; 39% women) with 62240 cases of coronary heart disease (CHD).

164 ailed to demonstrate a reduction in risk for coronary heart disease (CHD).

165 accepted model to predict outcomes in stable coronary heart disease (CHD).

166 their independent association with incident coronary heart disease (CHD, defined as myocardial infar

167 comes (ie, composite CVD, fatal and nonfatal coronary heart disease [CHD], and overall stroke and str

168 cord of 1 of 4 cardiovascular presentations (coronary heart disease [CHD], cerebrovascular disease, h

169 ntration with first-ever CVD outcomes (i.e., coronary heart disease [CHD], stroke, or the combination

170 d risk of cardiovascular disease, especially coronary heart disease, compared with people not infecte

171 We studied the future risk of heart failure, coronary heart disease, composite cardiovascular disease

172 o MI) were associated with increased risk of coronary heart disease death (hazard ratio, 3.06 [95% co

173 ring the initial trial phase and the risk of coronary heart disease death, cardiovascular death, and

174 e first occurrence of myocardial infarction, coronary heart disease death, congestive heart failure,

175 ids from baseline were correlated with MACE (coronary heart disease death, nonfatal myocardial infarc

176 Incident CVD, which combines coronary heart disease, defined as the first incident my

177 ncidence of most chronic conditions, such as coronary heart disease, dementia, stroke, fractures, and

178 blood cells of patients with lung cancer or coronary heart disease, diseases strongly associated wit

179 s being taken, and high CVD risk (history of coronary heart disease, estimated glomerular filtration

180 l of 1845 participants had an incident acute coronary heart disease event during 375 064 person-years

181 Participants who experienced an incident coronary heart disease event were excluded.

182 d nongenetic effects on the indexing (first) coronary heart disease event.

183 nefit from statin therapy to prevent a first coronary heart disease event.

184 CAC-guided reclassification, specificity for coronary heart disease events improved 22% (p < 0.0001)

185 rvational studies (166 486 individuals; 9784 coronary heart disease events) a 1 SD higher urate conce

186 There were 330 incident coronary heart disease events, 161 strokes, 1112 deaths,

187 low-up of 16 years, there were 1779 incident coronary heart disease events, 548 ischemic strokes, 139

188 factors accounted for 66% of the decline in coronary heart disease events.

189 al infarctions, unstable angina, deaths from coronary heart disease, fatal and nonfatal ischemic stro

190 le for troponin testing in the prevention of coronary heart disease has yet to be established.

191 tage where people at risk of severe or fatal coronary heart disease have a much better prognosis than

192 ygous familial hypercholesterolemia (FH) and coronary heart disease have high mortality rates.

193 ictor of myocardial infarction or death from coronary heart disease (hazard ratio [HR]: 2.3; 95% conf

194 nterval, 1.07-1.36) and a 26% higher risk of coronary heart disease (hazard ratio, 1.25; 95% confiden

195 .46; 95% confidence interval, 1.14-1.87) and coronary heart disease (hazard ratio, 1.56; 95% confiden

196 tional hazard models to compare the risks of coronary heart disease, heart failure, and mortality acc

197 associated with an increased risk of future coronary heart disease, heart failure, and stroke after

198 ncreases in the incidence and progression of coronary heart disease, heart failure, stroke, and atria

199 rains has been associated with lower risk of coronary heart disease; however, the research that has b

200 1,5-AG <6.0 mug/mL had an increased risk of coronary heart disease (HR 3.85, 95% CI 3.11-4.78), stro

201 .99 to 1.32), but higher risks of death from coronary heart disease (HR: 1.45; 95% CI: 1.21 to 1.74),

202 ECG) parameters in individuals free of prior coronary heart disease in four different ethnicities.

203 ciated with nearly a doubling in the risk of coronary heart disease in humans and with accelerated at

204 erentially effective in reducing the risk of coronary heart disease in individuals with smaller apoli

205 tionships between physical activity (PA) and coronary heart disease in longshoremen and in college at

206 re, a GPC shown recently to predict incident coronary heart disease in older adults, PC18:2/0:0, was

207 ned data from 3313 patients with established coronary heart disease in the Ludwigshafen Risk and Card

208 Identifying underlying coronary heart disease in this vulnerable population may

209 death and stroke in both sexes and incident coronary heart disease in women but not men (interaction

210 tality and ischemic stroke in both sexes and coronary heart disease in women.

211 ariants were associated with lower LDL-C and coronary heart disease incidence.

212 Factors associated with prevalent coronary heart disease included diabetes mellitus (adjus

213 Incident CVD (coronary heart disease, including nonfatal myocardial in

214 trogen (stroke), estrogen-progestin (stroke, coronary heart disease, invasive breast cancer, and pulm

215 se mortality among patients with established coronary heart disease is controversial.

216 easure to predict progression to death after coronary heart disease is established.

217 causal role of cystatin C in CVD, including coronary heart disease, ischemic stroke, and heart failu

218 INTERPRETATION: In patients with prevalent coronary heart disease, lipoprotein(a) concentrations an

219 moglobin concentration with total mortality, coronary heart disease mortality, and cancer mortality.

220 as associated with higher rates and risks of coronary heart disease mortality, myocardial infarction,

221 confidence intervals (CIs) for all-cause and coronary heart disease mortality, myocardial infarction,

222 al and nonfatal myocardial infarction, other coronary heart disease mortality, or stroke; (3) ASCV mo

223 ny coronary event (a composite of death from coronary heart disease, nonfatal myocardial infarction,

224 psilon2 was associated with reduced risk for coronary heart disease (odds ratio 0.77; P=1x10(-)(11)).

225 gnaling was associated with reduced risks of coronary heart disease (odds ratio, 0.37; 95% confidence

226 4; P=5.6*10(-5)) and a 3-fold higher risk of coronary heart disease (odds ratio, 3.03; 95% CI, 1.29-7

227 were associated with a pooled odds ratio for coronary heart disease of 0.51 (95% CI, 0.28-0.92) in bl

228 n was associated with an odds ratio (OR) for coronary heart disease of 1.07 (95% CI 1.04-1.10).

229 ort of older adults free of clinically overt coronary heart disease or heart failure, obesity was ass

230 diovascular disease was defined as non-fatal coronary heart disease or non-fatal stroke.

231 espectively 1,987 deaths and 680 adjudicated coronary heart disease or stroke events had occurred.

232 (95% CI 1.9-2.6) for vascular disease only (coronary heart disease or stroke), 12.0 (8.1-17.9) for v

233 A1369S was associated with a reduced risk of coronary heart disease (OR 0.98; 95% CI 0.96, 0.99; P =

234 , 1.64; 95% CI, 1.48-1.83; P = 1.1 x 10-19), coronary heart disease (OR, 1.35; 95% CI, 1.09-1.69; P =

235 Whether in heart failure, hypertension, or coronary heart disease, or even athletes, heart rate low

236 troke, nonfatal myocardial infarction, fatal coronary heart disease, or heart failure.

237 d participants with a diagnosis of diabetes, coronary heart disease, or stroke at or before study bas

238 03; 71 445 women) who did not have diabetes, coronary heart disease, or stroke at study baseline (197

239 Obesity, history of coronary heart disease (other than myocardial infarction

240 adjusted incidence rates were calculated for coronary heart disease overall, out-of-hospital sudden d

241 PHDL-C=0.008 and Ptriglycerides=0.00003) and coronary heart disease (P=0.0007).

242 ignaling is associated with reduced risks of coronary heart disease, peripheral arterial disease, and

243 Meta-analysis showed a lower risk of coronary heart disease (pooled RR: 0.88; 95% CI: 0.80, 0

244 onary angiography in patients with suspected coronary heart disease provides the opportunity to trans

245 uring each trip (Residential Environment and Coronary Heart Disease (RECORD) GPS Study, France, 2012-

246 ASCVD was defined as myocardial infarction, coronary heart disease-related death, or fatal or nonfat

247 ned a significantly lower risk of death from coronary heart disease (relative risk [RR] 0.89; 95% con

248 -term mortality in patients with established coronary heart disease remains less clear.

249 the effect of the genetic score on decreased coronary heart disease risk extended beyond its effect o

250 mmendations showed small overall benefits in coronary heart disease risk factors.

251 and comprehensive management of traditional coronary heart disease risk factors.

252 .0 to -1.1 mm Hg) at 6 months and Framingham coronary heart disease risk score at 18 months (-0.19 to

253 aimed to clarify any causal role of urate on coronary heart disease risk using Mendelian randomisatio

254 The 10-year coronary heart disease risk was low (median: 6.9%).

255 ention interventions may be needed to reduce coronary heart disease risk.

256 nsidering SMI in personalized assessments of coronary heart disease risk.

257 mellitus and prediabetes remain at increased coronary heart disease risk.

258 ed by the ABC-CHD (Age, Biomarkers, Clinical-Coronary Heart Disease) risk score (p for interaction =

259 bo, BP-lowering therapy reduced the risk for coronary heart disease (RR, 0.84; 95% CI, 0.79-0.90) and

260 9; 95% confidence interval [CI], 2.09-8.38), coronary heart disease (RR, 2.50; 95% CI, 1.43-4.37), ca

261 causal association of obesity with diabetes, coronary heart disease, specific cancers, and other cond

262 nt, greater PA was inversely associated with coronary heart disease, stroke (especially ischemic stro

263 iffness and various cardiovascular outcomes (coronary heart disease, stroke) remains after adjusting

264 The hazard ratios for incident coronary heart disease, stroke, and CVD associated with

265 heart failure and a 2-fold increased risk in coronary heart disease, stroke, and death because of cor

266 sex, race, diabetes mellitus, hypertension, coronary heart disease, stroke, and GEH parameters as co

267 consumption, and bodyweight for deaths from coronary heart disease, stroke, cancer, and an aggregate

268 Resulting changes in life-years lost due to coronary heart disease, stroke, diabetes, and cancers we

269 ls with a history of cardiovascular disease, coronary heart disease, stroke, diabetes, heart failure,

270 Composite CVD events, including coronary heart disease, stroke, heart failure, and other

271 omes of major cardiovascular disease events, coronary heart disease, stroke, heart failure, renal fai

272 ciations of erythropoietin with incident HF, coronary heart disease, stroke, mortality, and >/= 30% d

273 utcome and Measures: Incident CVD, including coronary heart disease, stroke, or death from cardiovasc

274 rsonality domain with death from all causes, coronary heart disease, stroke, respiratory disease, or

275 omes were the number of deaths attributed to coronary heart disease, stroke, sudden death from an unk

276 obesity on her offspring's risks of obesity, coronary heart disease, stroke, type 2 diabetes, and ast

277 alth-care costs and DALYs were estimated for coronary heart disease, stroke, type 2 diabetes, breast

278 Evaluation of MAgnetic Resonance imaging in Coronary heart disease) study for a minimum of 5 years f

279 ed by using saphenous vein segments from non-coronary heart disease subjects after phlebotomies.

280 This paper discusses primary prevention of coronary heart disease that may be achieved through modi

281 tive cohorts, carriers of CHIP had a risk of coronary heart disease that was 1.9 times as great as in

282 ed a substantial decline in the incidence of coronary heart disease that was driven by reductions in

283 here is no effect modification by history of coronary heart disease, the false-positive rates of asso

284 Specifically, for coronary heart disease, the hazard ratios for 20% increa

285 al perspective on the presence or absence of coronary heart disease to accepting the risk continuum f

286 Conclusion In older adults without prior coronary heart disease, underlying greater LV diffuse fi

287 ons in NOS3 and GUCY1A3 were associated with coronary heart disease using gene sequencing data from t

288 lood cells and associated such presence with coronary heart disease using samples from four case-cont

289 Coronary heart disease was an independent predictor of m

290 Increased severity of coronary heart disease was associated with lipoprotein(a

291 Information on total CVD, stroke, and coronary heart disease was obtained through a hospital d

292 Prevalent coronary heart disease was reported in 36% of patients,

293 with clinical cardiac dysfunction, prevalent coronary heart disease was the only factor independently

294 l features, absence of any family history of coronary heart disease was the strongest (DLRs, 0.76 [SD

295 y of APOC3 has been shown to protect against coronary heart disease; we identified APOC3 homozygous p

296 with incident HF, CV-related mortality, and coronary heart disease were estimated using Cox regressi

297 hat the CETP inhibitor anacetrapib decreased coronary heart disease when added to statin therapy.

298 One hundred fifty-one outpatients with coronary heart disease who were 36 to 84 years of age we

299 Despite the reduced incidence of coronary heart disease with intensive risk factor manage

300 he body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according